Critical Survey: Mangoceuticals (NASDAQ:MGRX) and Concord Medical Services (NYSE:CCM)

Concord Medical Services (NYSE:CCM) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Institutional and Insider Ownership

56.7% of Mangoceuticals shares are held by institutional investors. 46.5% of Concord Medical Services shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Concord Medical Services and Mangoceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85 million	0.32	-$13.27 million	N/A	N/A
Mangoceuticals	$460,000.00	19.61	-$20.64 million	($1.01)	-0.41

Concord Medical Services has higher revenue and earnings than Mangoceuticals.

Analyst Recommendations

This is a summary of current ratings and target prices for Concord Medical Services and Mangoceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1	0	0	0	1.00
Mangoceuticals	1	0	0	0	1.00

Profitability

This table compares Concord Medical Services and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Volatility & Risk

Concord Medical Services has a beta of -0.97, indicating that its stock price is 197% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Summary

Concord Medical Services beats Mangoceuticals on 6 of the 9 factors compared between the two stocks.

About Concord Medical Services

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.